



# 2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

## HBV

APASL STC 2018

## Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center  
Taipei, Taiwan



## Koichi Watashi

### CURRENT POSITIONS

Senior Researcher, National Institute of Infectious Diseases, Department of Virology II

### EDUCATIONAL AND CAREER EXPERIENCES

- 1994-1998: Kyoto University, Faculty of Pharmaceutical Sciences
- 1998-2003: Kyoto University Graduate School of Pharmaceutical Sciences (Mentor: Prof. K Shimotohno)
- 2003-2003: Post Doctoral Fellow, Japan Society of the Promotion of Science
- 2004-2008: Assistant Professor, Institute for Virus Research, Kyoto University
- 2007-2009: Visiting Fellow, National Institutes of Health (NIH), USA (Mentor: Dr. KT Jeang)
- 2009-present: Senior Researcher, Department of Virology II, National Institute of Infectious Diseases
- 2011-present: (Dual-appointment) Visiting Associate Professor, Tokyo University of Science
- 2017-present: (Dual-appointment) Distinguished Chair Professor, Nanchang University

### PUBLICATION/ AWARDS AND HONORS/ OWNED PATENTS

(Awards)

Incitement Award of The Japanese Cancer Association (2007), Sugiura Memorial Incentive Award of The Japanese Society for Virology (2007), Young Investigator Award of The Japan Society of Hepatology, STC (2012), Taisho-Toyama Award (2016); MSD Award of The Japan Society of Hepatology (2017)

(Recent Publications)

- 1) Tsukuda S et al. A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on viral large surface proteins. *Hepatology* 65:1104-1116 (2017) (\*corresponding author: Watashi K)
- 2) Ohashi H et al. Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments. *Proc Natl Acad Sci USA* 114:E4527-E4529 (2017) (\*corresponding author: Iwami S and Watashi K)
- 3) Shimura S et al. Cyclosporin derivatives inhibit hepatitis B virus entry without interfering the NTCP transporter. *J Hepatol* 66:685-692 (2017) (\*corresponding author: Watashi K)
- 4) Koizumi Y et al. Quantifying antiviral activity optimizes drug combinations against hepatitis C virus infection. *Proc Natl Acad Sci USA* 114:1922-1927 (2017) (\*corresponding author: Iwami S and Watashi K)
- 5) Nakajima S et al. Fungus-derived neoechinulin B as a novel antagonist of liver X receptor, identified by chemical genetics using a HCV cell culture system. *J Virol* 90:9058-9074 (2016) (\*corresponding author: Watashi K)



# 2018 APASL Single Topic Conference on Hepatitis B Virus Taipei

# HBV

APASL STC 2018

## Towards Hepatitis B Elimination - Following Hepatitis C Cure

June 22-24

Taipei International Convention Center  
Taipei, Taiwan



- 6) Kaneko M et al. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting NTCP. *J Virol* 89:11945-11953 (2015) (\*corresponding author: Watashi K)
- 7) Tsukuda S et al. Dysregulation of retinoic acid receptor diminishes hepatocyte permissiveness to HBV infection through modulation of NTCP expression. *J Biol Chem* 290:5673-5684 (2015) (\*corresponding author: Watashi K)
- 8) Daito T et al. Cyclophilin inhibitors reduce phosphorylation of protein kinase PKR to restore expression of IFN- stimulated genes in HCV-infected cells. *Gastroenterology* 147:463-472 (2014) (\*corresponding author: Watashi K)